Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lymphoma Patients' vaccine response under scrutiny

NCT ID NCT05050461

Knowledge-focused Sponsor: Versailles Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how well the COVID-19 vaccine works in adults with B-cell non-Hodgkin lymphoma, especially those who received a common treatment called anti-CD20 monoclonal antibodies in the past year. Researchers compared antibody and T-cell responses between treated and untreated patients to understand if prior therapy weakens vaccine protection. The goal was to guide future vaccine and treatment recommendations for this vulnerable group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

120 people

The number who actually took part.

Started

Nov 2021

Finished

Nov 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult aged at least 18 years old * Having received (at least) two injections of anti-SARS-CoV-2 messenger RNA vaccine (Pfizer and / or Moderna) * Affiliated to social security * consenting to the study * Concerning cases only: Be or have been affected by B-NHL in remission, active surveillance or during first-line or second-line treatment, regardless of this treatment Exclusion Criteria: Patient less than 18 years old * Patient with protective measure (curatorship, guardianship, safeguard of justice, deprived of liberty, in an emergency situation) * Patient unable to express their consent * Pregnant or breastfeeding woman * Patient refusing to participate * Concerning cases: Patient whose life expectancy related to B-NHL is less than 6 months, History of allogeneic hematopoietic stem cell transplantation, Patient with CART cells treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-Hodgkin lymphoma, B-cell are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

B-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-Hodgkin lymphoma, B-cell Vaccination failure

Contacts and locations

Locations

  • André Mignot -Versailles Hospital, Hemato-oncology unit

    Le Chesnay, Île-de-France Region, 78150, France

  • Emile Muller Hospital, Hematology unit

    Mulhouse, 68100, France

  • Hospitals of Brabois, Hematology unit

    Vandœuvre-lès-Nancy, 54500, France

  • Institut of Cancerology Strasbourg Europe (ICANS), Hematology deparment

    Strasbourg, 67000, France

  • Pitié Salpêtrière Hospital, Hematology unit

    Paris, Île-de-France Region, 75013, France

  • Saint Antoine Hospital, Hematology unit

    Paris, Île-de-France Region, 75012, France

  • saint Louis Hospital, Hemato-oncology unit

    Paris, Île-de-France Region, 75010, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.